EXPERTISE

Mahreen’s industry experience and her time in the U.S. Patent and Trademark Office (USPTO) allow her a unique perspective of being able to see applications from many vantages. With Elmore Patent Law Group since 2007, she drafts and prosecutes patent applications specializing in biotechnology and pharmaceutical technology areas. Mahreen also excels at instructing and collaborating with foreign associates on prosecution of foreign patent applications. She works with clients to build a patent portfolio development strategy and then helps them realize their goals.

PATENT LAW EXPERIENCE

Mahreen has meaningful experience with the USPTO and in industry. As Senior Patent Agent at Critical Therapeutics, Inc., a biopharmaceutical company focused on the development of products for inflammatory disease, she was responsible for managing the company’s patent portfolio including expanding the portfolio from about ten patent families to nearly fifty patent families. Prior to working at Critical Therapeutics, Mahreen was a Patent Examiner at the USPTO in an organic chemistry group (Art unit 1623 - Organic Chemistry and Enzyme Assays).

PREVIOUS POSITIONS

Prior to joining Elmore Patent Law Group, Mahreen was Senior Patent Agent at Critical Therapeutics, Inc. She also worked as a Patent Examiner with the U.S. Patent and Trademark Office.

EDUCATION

• J.D. Suffolk University Law School, Boston, MA
• M.S. Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA
• B.A. Psychology, Pre-Med; University of Virginia, Charlottesville, VA

BAR ADMISSIONS

• Bar of the Commonwealth of Massachusetts (2008)
• Bar of the United States Patent and Trademark Office (2002)

ASSOCIATIONS

• Boston Patent Law Association
• American Intellectual Property Law Association

PUBLICATIONS

• Mahreen Hoda and Penny Prater, De Novo Review of Claim Construction Issues at the Federal Circuit - What it Means for the Butamax v. Gevo Litigation, AIPLA Chemical Practice Chronicles, Fall 2014
• Mahreen Hoda, An Undefined Claim Term Can Be Interpreted as Having Different Meanings in Different Contexts: Aventis Pharm. Inc. v. Amino Chemicals Ltd., AIPLA Chemical Practice Chronicles, Fall 2013
• Chaudhry, M., Sundaram, S., Gennings, C., Carter, H. and Gewirtz, D. A., The Vitamin D₃ Analog ILX 23-7553 Enhances the Response to Adriamycin and Irradiation in MCF-7 Breast Tumor Cells, Cancer Chemotherapy and Pharmacology, 47(5):429-36 2001
• Sundaram, S., Chaudhry, M., Reardon, D. and Gewirtz, D. A., EB 1089 Enhances the Antiproliferative and Apoptotic Effects of Adriamycin in MCF-7 Breast Tumor Cells, Breast Cancer Research and Treatment, 63(1):1-10 2000